Position in GRFS
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$4,849
-$11,062 QoQ
Shares Held
685
-65.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#135
of 164 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Farther Finance Advisors, LLC holds $187,005,351 across 18 Drug Manufacturers - General names. GRFS ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
43,809 | $52,545,833 | |
| 2 | JNJ |
Johnson & Johnson
|
135,612 | $34,441,379 | |
| 3 | ABBV |
AbbVie Inc.
|
119,959 | $30,186,482 | |
| 4 | MRK |
Merck & Co., Inc.
|
120,685 | $15,508,022 | |
| 5 | AMGN |
Amgen Inc
|
34,711 | $12,569,547 | |
| 6 | PFE |
Pfizer Inc
|
395,297 | $9,518,751 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
148,017 | $8,528,739 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
58,478 | $7,388,110 |
All Filings in GRFS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,849 | 685 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $15,911 | 1,984 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $15,352 | 1,642 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $16,204 | 1,627 | Shares | Sole | 2025-10-14 | |
| 2025-06-30 | $9,058 | 1,002 | Shares | Sole | 2025-07-11 | |
| 2025-03-31 | $6,441 | 906 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $11,316 | 1,521 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $2,903 | 327 | Shares | Sole | 2024-10-29 | |
| 2024-06-30 | $3,413 | 541 | Shares | Sole | 2024-07-31 | |
| 2023-12-31 | $2,312 | 200 | Shares | Sole | 2024-02-15 | |
| No filing history on record for this holder in this stock. | ||||||